Φορτώνει......
Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?
Biosimilars are being marketed in India since 2000. Like biologics, biosimilars have a large size, complex structure, and complicated manufacturing process, and they are produced in a living organism. It requires specialized delivery devices for administration and needs tighter temperature control t...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Postgrad Med |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Wolters Kluwer - Medknow
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6813686/ https://ncbi.nlm.nih.gov/pubmed/31571620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/jpgm.JPGM_109_19 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|